Molecular and clinical effects of selective TYK2 inhibition with deucravacitinib in psoriasis

Study ID Alternative Stable ID Type
EGAS00001005875 Other

Study Description

Investigate changes in IL-23/Th17- and type I interferon-pathway biomarkers and gene responses, and measures of selectivity for TYK2 over Janus kinases (JAKs) 1–3, in patients with moderate to severe psoriasis receiving deucravacitinib.

Study Datasets 1 dataset.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
Transcriptomic profiling of skin biopsies from psoriasis patients following treatment with deucravacitinib

Who archives the data?

There are no publications available